To compare adherence (proportion of days covered [PDC]), persistence, and treatment patterns among patients with type 2 diabetes mellitus (T2DM) newly initiating glucagon-like peptide-1 receptor agonists (GLP-1RAs). More specifically, the main objectives were to compare dulaglutide vs exenatide once weekly and dulaglutide vs liraglutide. Results: Mean adherence for the matched cohorts was significantly higher for dulaglutide than for exenatide once weekly (0.72 vs 0.61; P < .0001) and liraglutide (0.71 vs 0.67; P < .0001).
| INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic, progressive metabolic disease characterized by persistent hyperglycaemia resulting from β-cell dysfunction and worsening of insulin resistance. 1 More than 29.1 million people in the USA have diabetes (21 million diagnosed;
8.1 million undiagnosed), with T2DM accounting for 95% of cases. 2 The lifetime risk of developing T2DM has risen significantly, from 20% in the period 1985 to 1989 to 40% in 2000 to 2011 for men and from 27% to 39% for women. 3 Optimum glycaemic control in T2DM may be achieved by diet and lifestyle management alone, or along with use of any of several classes of oral antidiabetic drugs (OADs) as monotherapy or combination therapy. [4] [5] [6] As the disease progresses, injectable therapies such as insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs)
can be used, usually as combination treatment. [7] [8] [9] Despite the availability of multiple therapeutic options, only 36% of patients with T2DM
achieve optimum glycaemic control, and an estimated 14.9% of US adults with uncontrolled diabetes do not take any medications. 2, 8 Medication adherence and persistence are critical for the effectiveness of antidiabetic therapies. 8 A systematic review of adherence data from retrospective/prospective electronic monitoring studies found a wide range of adherence rates to OADs, ranging from 36%
to 93%, and 62% to 64% adherence to insulin therapy. 10 Increased adherence to antidiabetic agents has been shown to improve glycaemic control and reduce healthcare utilization, mortality and diabetesrelated complications (glycated haemoglobin [HbA1c] levels, diabetic ketoacidosis and cardiovascular disease). [10] [11] [12] [13] Medication adherence has also been associated with lower disease-related healthcare costs. 14, 15 Even adherence to treatment regimens with relatively high pharmacy costs has been found to reduce overall healthcare costs. 16 In addition, studies have shown simpler and less frequent dosing regimens are associated with increased adherence. 17, 18 The GLP-1RAs, also known as incretin mimetics, are a relatively new class of injectable antidiabetic drugs 19 that reduce hyperglycaemia by stimulating glucose-dependent insulin secretion, suppressing postprandial glucagon release in a glucose-dependent manner, and inducing satiety. 20, 21 Controlled clinical trials and retrospective studies have shown GLP-1RAs to be an effective therapeutic option for achieving optimum glycaemic targets, [22] [23] [24] and they are included in treatment guidelines. For example, the American Association of Clinical Endocrinologists guidelines recommend the use of GLP-1RAs as the first therapeutic choice after metformin 6 and the American Diabetes Association and the European Association for the Study of Diabetes guidelines recommend GLP-1RAs as one of the treatment options after metformin 5, 7 for patients with inadequately controlled T2DM.
During the study period, 5 GLP-1RAs had been approved by the US Food and Drug Administration (FDA) for the treatment of T2DM:
exenatide twice daily (Byetta), exenatide once weekly (Bydureon), liraglutide once daily (Victoza), albiglutide once weekly (Tanzeum), and dulaglutide once weekly (Trulicity). A sixth GLP-1RA, lixisenatide (Adlyxin), received approval from the FDA on July 28, 2016, after the study was completed. 25 Previous studies have shown significant differences in adherence among patients with T2DM newly initiating exenatide once weekly, exenatide twice daily, or liraglutide. 23, 26, 27 Some studies suggested better adherence with exenatide once weekly than liraglutide, 23 23, [28] [29] [30] [31] [32] The databases satisfy the conditions of statistically de-identified data as set forth in the Health Insurance Portability and Accountability Act of 1996. As this study used only de-identified patient data, it was exempted from institutional review board approval. 
| Patient selection

| Outcome measures
Adherence, measured by proportion of days covered (PDC) 
| Statistical analysis
Baseline demographics and clinical characteristics were summarized and compared using a t-test for continuous variables and a chisquared test for categorical variables. Because patients were not randomized to treatment, propensity score matching was used to adjust for possible treatment selection bias for each comparison: dulaglutide vs exenatide once weekly and dulaglutide vs liraglutide. The propensity score was defined as the probability of assignment to the dulaglutide cohort given the baseline characteristics. The characteristics listed in Tables 1 and 2 served as covariates in a logistic regression to generate a propensity score for each patient. These variables were selected a priori based on previously identified variables of interest in a comparison of liraglutide and exenatide once weekly. 27 Patients on dulaglutide were matched 1:1 to those on exenatide once weekly using a greedy matching algorithm with a caliper of 0.2x standard deviation of the logit of the propensity score. Analyses were conducted in SAS version 9.4 (Cary, NC, USA). Tables 1 and 2 show the demographic and clinical characteristics of the dulaglutide vs exenatide once-weekly and dulaglutide vs liraglutide cohorts before and after propensity score matching, respectively. During the pre-index period, 42.4% of matched dulaglutide patients were prescribed insulin, 27.4% were prescribed a sodiumglucose co-transporter-2 (SGLT2) inhibitor, and 31.5% were prescribed a non-index GLP-1RA compared with 41.9%, 26.6% and 31.5% of matched patients in the exenatide once-weekly cohort, respectively (Table 1) . For the second matched cohort, 41.7% of patients on dulaglutide were prescribed insulin, 26.0% were prescribed an SGLT2 inhibitor, and 17.8% a non-index GLP-1RA compared with 42.5%, 27.3%, and 17.8% of matched patients in the liraglutide cohort, respectively. After matching, all key demographics and pre-index characteristics were balanced.
| RESULTS
Between
A list of prescribed antidiabetic medications used in the postindex period for both matched cohorts is shown in Table S1 . Across both matched cohorts, the most frequent medications used during the post-index period were metformin, sulphonylureas, insulin and SGLT2 inhibitors. 
| Adherence
| Persistence
The Propensity scores were calculated using the baseline covariates age, gender, geographic location, and health plan type on the index date; Charlson comorbidity index, presence of cardiovascular disease, hyperlipidaemia, obesity, gastrointestinal diagnosis or medication; total copayment and coinsurance across all pharmacy claims observed during the baseline period; total copayment and coinsurance on index claim; number of prescription drug classes, use of non-index GLP-1 (exact match), insulin, SGLT2, and DPP-4 inhibitor during the baseline period; presence of HbA1c test claim pre-index; presence and number of endocrinologist visits pre-index; and number of inpatient admissions and office visits pre-index. Propensity scores were calculated using the baseline covariates age, gender, geographic location, and health plan type on the index date; Charlson comorbidity index, presence of cardiovascular disease, hyperlipidaemia, obesity, gastrointestinal diagnosis or medication; total copayment and coinsurance across all pharmacy claims observed during the baseline period; total copayment and coinsurance on index claim; number of prescription drug classes, use of non-index GLP-1 (exact match), insulin, SGLT2 and DPP-4 inhibitor during the baseline period; presence of HbA1c test claim pre-index; presence and number of endocrinologist visits pre-index; and number of inpatient admissions and office visits pre-index. 
| Treatment switching
A total of 6.6% of matched patients in the dulaglutide cohort and 11.4% (P < .0001) of those in the exenatide once-weekly cohort switched antidiabetic agents during the post-index period. Among matched patients, 2.3% of dulaglutide patients switched to a different GLP-1RA during the post-index period, compared with 3.8% of patients on exenatide once weekly (P = .0034). Liraglutide was the most commonly switched to GLP-1RA in both cohorts (1.1% from dulaglutide and 1.9% from exenatide once weekly; P = .0231; Figure   S2A ). Patients in the exenatide once-weekly cohort more frequently switched to another antidiabetic medication class than those in the dulaglutide cohort (8.2% vs 4.8%; P < .0001). SGLT2 inhibitors were the most frequently switched-to medication class for both cohorts (1.1% dulaglutide, 2.7% exenatide once weekly, P < .0001; Figure S2A ).
In switched to insulin (1.6%), followed by SGLT2 inhibitors (1.5%; Figure S2B ).
| Treatment augmentation
A total of 4.3% of matched patients in the dulaglutide cohort and 9.4% (P < .0001) of patients in the exenatide once-weekly cohort augmented their index drug with another antidiabetic medication during the post-index period. Among both cohorts, the highest proportion of patients augmented with SGLT2 inhibitors (1.5% for dulaglutide, 2.9% exenatide once weekly; P = .0006; Figure S3A ). In the matched comparison between dulaglutide and liraglutide, 4.6% of patients in the dulaglutide cohort and 6.2% (P = .0265) of those in the liraglutide cohort augmented therapy during the post-index period. SGLT2 inhibitors were the most frequent augmentation class for patients on dulaglutide (1.6%), while those on liraglutide most frequently augmented with insulin (2.0%; Figure S3B ).
| Analysis of all 5 GLP-1RAs
The findings of improved adherence for dulaglutide in the 2 separate Figure S4 ). In the IPTW Cox regression model, patients on dulaglutide were significantly less likely to discontinue treatment over the 6-month post-index period than patients on albiglutide, exenatide twice daily, exenatide once weekly, and liraglutide ( Figure S5 ). Adherence to prescribed therapies is a primary determinant of treatment effectiveness in patients with T2DM.
39 Treatment nonadherence among patients with T2DM has been associated with increased rates of hospitalization and mortality. 12, 40 By contrast, an increase in adherence and persistence is likely to result in better glycaemic control 11, 22, 41 and economic outcomes. . 23 In a more recent study, patients with T2DM treated with exenatide once weekly had slightly higher adherence and slightly lower persistence profiles compared with liraglutide; 27 however, these studies used data obtained prior to the availability of dulaglutide in the USA.
Higher adherence and persistence with dulaglutide over liraglutide may be related to its simplified dosing-once weekly for dulaglutide vs once daily for liraglutide. 
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